Kaposi's sarcoma associated with highly active antiretroviral therapy

被引：1
|
作者：
Crane, HM
Deubner, H
Huang, JC
Swanson, PE
Harrington, RD
机构：
[1] Univ Washington, Div Allergy & Infect Dis, Seattle, WA 98104 USA
[2] Univ Washington, Dept Pathol, Seattle, WA 98104 USA
来源：
INTERNATIONAL JOURNAL OF STD & AIDS | 2005年 / 16卷 / 08期
关键词：
D O I：
10.1258/0956462054679133
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：583 / 583
页数：1
相关论文
共 50 条
  • [31] Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals
    Zala, C
    Ochoa, C
    Krolewiecki, A
    Patterson, P
    Cahn, P
    Crawford, RI
    Montaner, JSG
    AIDS, 2000, 14 (14) : 2217 - 2218
  • [32] Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy
    Niehues, T
    Horneff, G
    Megahed, M
    Schroten, H
    Wahn, V
    AIDS, 1999, 13 (09) : 1148 - 1149
  • [33] Kaposi's sarcoma in pregnancy after initiation of highly active antiretroviral therapy: a manifestation of immune reconstitution syndrome
    Adeyemo, A.
    Wood, C.
    Govind, A.
    INTERNATIONAL JOURNAL OF STD & AIDS, 2012, 23 (12) : 905 - 906
  • [34] Potential drug interaction with paclitaxel and highly active antiretroviral therapy in two patients with AIDS-associated Kaposi sarcoma
    Bundow, D
    Aboulafia, DM
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (01): : 81 - 84
  • [35] Highly active antiretroviral therapy (HAART) is active as anti-Kaposi's sarcoma (KS) therapy: Results of a trial in 53 patients (PTS)
    Vaccher, E
    Maserati, R
    Mongiovetti, M
    Nasti, G
    Fasan, M
    Vigan, MG
    Bottura, P
    Mena, M
    Pan, A
    Demichieli, A
    Chieppa, F
    Bertelli, D
    Accurso, V
    Di Gennaro, GP
    Schioppa, O
    Tirelli, U
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (03) : A22 - A22
  • [36] Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response
    Nguyen, Huong Q.
    Magaret, Amalia S.
    Kitahata, Mari M.
    Van Rompaey, Stephen E.
    Wald, Anna
    Casper, Corey
    AIDS, 2008, 22 (08) : 937 - 945
  • [37] Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy
    Aboulafia, DM
    MAYO CLINIC PROCEEDINGS, 1998, 73 (05) : 439 - 443
  • [38] Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy
    Hesseling, P. B.
    Katayi, E.
    Wharin, P.
    Bardin, R.
    Kouya, F.
    Palmer, D.
    Glenn, M.
    Kruger, M.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2017, 107 (11): : 952 - 953
  • [39] Regression of Clinically Diagnosed Ocular Kaposi Sarcoma Post-Initiation of Highly Active Antiretroviral Therapy
    Francis, Cheyanne
    Da Silva, Kirsten
    Grosvenor, Dawn
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2025, 112 (03)
  • [40] Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy
    S Franceschi
    L Dal Maso
    M Rickenbach
    J Polesel
    B Hirschel
    M Cavassini
    A Bordoni
    L Elzi
    S Ess
    G Jundt
    N Mueller
    G M Clifford
    British Journal of Cancer, 2008, 99 : 800 - 804
12345